



PRESS RELEASE

AMOÉBA informs on the status of the applications for registration of its biocidal product in the United States and Canada

Lyon (France), February 1st, 2019 - AMOÉBA (FR0011051598 - AMEBA), producer of a biological biocide capable of eliminating bacterial risk in water, plant protection and wound care applications, informs on the status of the applications for registration of its biocidal product in the United States and Canada

In the United States:

The registration of the biocidal active substance *Willaertia magna C2c Maky* and the biocidal product BIOMEBA in the United States is in its final phase of evaluation (see Press Release dated 12 September 2018). As a result of the government shutdown, the non-essential functions of the EPA (Environmental Protection Agency), including biocidal products evaluations, ceased entirely between December 29, 2018 and January 28, 2019. The Company believes that this situation could have an impact on the EPA's decision date, scheduled for the first quarter of 2019. To date, such additional time is neither confirmed nor quantifiable by the Company.

In Canada:

The Company has submitted to the Pest Management Regulatory Agency (PMRA) an application to register the active substance and the biocidal product BIOMEBA for the purpose of marketing. BIOMEBA is intended to prevent *Legionella pneumophila* proliferation and to control biofilm in industrial water systems, including cooling towers.

The duration of the approval procedure is estimated to be 24 months. The Company estimates that the commercialization of BIOMEBA in Canada could be possible at the earliest in the first quarter of 2021, subject to PMRA approval.

On January 9, 2019, the PMRA has renewed the BIOMEBA marketing authorization for research purpose, which allows the Company to conduct industrial-scale trials in Quebec and Ontario.



About AMOÉBA:

Amoéba's ambition is to become a major player in the treatment of bacterial risk in the fields of water, healthcare and plant protection. Our biological solution is an alternative to chemical products widely used today. Amoéba is currently focusing on the market of industrial cooling towers estimated at €1.7Bn ⁽¹⁾ on a global chemical



biocide market for water treatment, evaluated at €21Bn ⁽²⁾ and on the biocontrol market for plant protection estimated globally at €1.6Bn ⁽⁴⁾. In the future, the Company is looking at developing new applications such as chronic wound care, estimated at € 751 million ⁽³⁾ in the USA. Sales of associated products with healthcare, biocides and crop protection are subject to the Company being granted local regulatory market authorizations. Created in 2010, based in Chassieu (Lyon, France) with a subsidiary in Canada and in the United States, Amoéba is quoted on the compartment C of Euronext Paris. The Company is a member of the BPIfrance Excellence network and is eligible for the PEA-PME SME equity savings plan setup. More information on www.amoeba-biocide.com.

(1): Amoéba data combined from sources: DRIRE 2013, Eurostat, ARHIA 2013

(2): Sources combined by Amoéba from water treaters, Freedonia, Eurostat et MarketsandMarkets

(3): BCC Research, "Markets for Advanced Wound Management Technologies," Wellesley, MA, 2017

(4): Biopesticides Worldwide Market 2013, CPL, Wallingford, UK

Contacts :

Amoéba

Valérie FILIATRE

Directeur administratif et Financier

04 26 69 16 00

valerie.filiatre@amoeba-biocide.com

Actifin

Ghislaine GASPARETTO

Communication financière

01 56 88 11 11

ggasparetto@actifin.fr

Disclaimer

This press release contains certain forward-looking statements concerning AMOEBA which are based on its own assumptions and hypothesis and on information that are available to us. However, AMOEBA gives no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the reference document of AMOEBA filed with the French Financial Markets Authority (*Autorité des Marchés Financiers*) on April 27, 2018 (a copy of which is available on www.amoeba-biocide.com). The forward-looking statements contained in this press release are also subject to risks not yet known to AMOEBA or not currently considered material by AMOEBA. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of AMOEBA to be materially different from such forward-looking statements.